Open Payments

Sutter Santa Rosa Regional Hospital

Type
Teaching hospital
Where
SANTA ROSA, CA
Medicare CCN
050291
Received
$194,949 in 17 records, 2024 ($10,925 general, $184,024 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment7$10,925
2024Research payment10$184,024

By company

CompanyRecordsAmountYears
AstraZeneca UK Limited1$59,4472024
AstraZeneca Pharmaceuticals LP3$49,3282024
Hoffmann-La Roche Limited3$30,2022024
Alexion Pharmaceuticals, Inc.1$20,9002024
ABBVIE INC.2$19,0392024
Biosense Webster, Inc.1$7,6072024
Pacira Pharmaceuticals Incorporated2$5,1742024
Linvatec Corporation1$2,8932024
Masimo Corporation1$1712024
Medline Industries LP1$1492024
Zimmer Biomet Holdings, Inc.1$362024

By nature of payment

NatureRecordsAmount
Research payment10$184,024
Long term medical supply or device loan4$8,239
Space rental or facility fees (teaching hospital only)1$2,500
Debt forgiveness2$186

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31ABBVIE INC.$1,772Research paymentIn-kind items and servicesM21-341 ATH Ph 2b Armour Thyroid vs Synthetic T4 (ATH-MD-01) (3014-301-002)2024
2024-12-31Masimo Corporation$171Long term medical supply or device loanCash or cash equivalentEMMA and ISA Device, Devices2024
2024-12-31Medline Industries LP$149Debt forgivenessCash or cash equivalent2024
2024-12-31Zimmer Biomet Holdings, Inc.$36Debt forgivenessCash or cash equivalent2024
2024-10-01Linvatec Corporation$2,893Long term medical supply or device loanIn-kind items and servicesAIRSEAL Device, GENERAL SURGERY2024
2024-09-17Alexion Pharmaceuticals, Inc.$20,900Research paymentCash or cash equivalentA Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2052024
2024-08-23AstraZeneca Pharmaceuticals LP$42,868Research paymentCash or cash equivalentA Two Part Phase IIa b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to A2024
2024-08-07AstraZeneca UK Limited$59,447Research paymentCash or cash equivalentTruqap Drug, OncologyA Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetax2024
2024-06-25Pacira Pharmaceuticals Incorporated$2,587Long term medical supply or device loanIn-kind items and servicesIovera Device, Pain Management2024
2024-06-25Pacira Pharmaceuticals Incorporated$2,587Long term medical supply or device loanIn-kind items and servicesIovera Device, Pain Management2024
2024-06-06ABBVIE INC.$17,267Research paymentCash or cash equivalentStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse2024
2024-05-29AstraZeneca Pharmaceuticals LP$3,960Research paymentCash or cash equivalentFARXIGA Drug, Cardiovascular and MetabolismDapagliflozin in Acute Decompensated Heart Failure2024
2024-05-03AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentLYNPARZA Drug, Oncology2024
2024-01-26Biosense Webster, Inc.$7,607Research paymentCash or cash equivalentAssessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI IRE Ablation System2024
2024-01-16Hoffmann-La Roche Limited$26,670Research paymentCash or cash equivalentA Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy 2024
2024-01-16Hoffmann-La Roche Limited$2,781Research paymentCash or cash equivalentA Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy 2024
2024-01-16Hoffmann-La Roche Limited$750Research paymentCash or cash equivalentA Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy 2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Sonoma CountySanta Rosa city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Santa Rosa, CA, county Sonoma County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Santa Rosa, CA
County
Sonoma County, CA
State
California
Population B01003177,090485,04039,287,377
Population, 2020 census P1178,127488,86339,538,223
Median age B0100241.242.937.9
Under 18 B0100120.1%19.0%22.0%
65 and over B0100119.0%21.5%15.7%
Households B1100168,321190,99813,548,091
Foreign born B0500221.2%16.8%27.0%
Median household income B19013$99,060$104,674$99,122
Median family income B19113$120,944$126,900$113,346
Per capita income B19301$52,066$56,640$49,513
Poverty rate B170019.7%8.9%12.0%
Unemployment rate B230256.3%5.7%6.6%
Civilian labor force B2302596,710258,15520,068,466
Mean commute (minutes) B0801322.925.128.7
Bachelor's degree or higher B1500335.1%38.5%37.1%
Housing units B2500171,382207,69914,644,735
Owner-occupied B2500356.7%62.6%55.9%
Renters B2500343.3%37.4%44.1%
Median home value B25077$713,900$815,500$734,700
Median gross rent B25064$2,152$2,158$2,036
White, not Hispanic B0300248.7%57.9%33.8%
Black B030021.9%1.5%5.2%
Hispanic or Latino B0300237.4%30.0%40.2%
Asian B030026.3%4.3%15.3%
American Indian and Alaska Native B030020.3%0.3%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Santa Rosa, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.